Cellular Biomedicine Group Announces Breakthrough for Solid Tumor Treatment
Watch the Video Report on Small Cap Nation
Marina del Rey – November 12, 2105 – Small Cap Nation reports that Cellular Biomedicine Group (NASDAQ:CBMG) has published positive results for its Cart-T cancer therapy clinical trial. CBMG’s Cart-T utilizes the body’s own cells to fight off tumor growth and kill off cancer cells. Accordingly, patients do not need to be subjected to chemo therapy with its negative side effects, often times killing cancer cells while at the same time also killing healthy body cells.
Please watch the Small Cap Nation Video Report on CBMG featuring comments from Dr. Yihong Yao, Chief Scientific Officer of CBMG and John McCamant, Editor and Publisher of Bioinvets.com.
Continuing Improvement for CBMG Development and Stock
StockWatchIndex (SWI) initiated coverage of CBMG in February of 2015 at $16.50 and while the stock is currently below its 52 week high, it has demonstrated consistent improvement over the last few weeks, we expect it to perform increasingly well moving forward and consider it a strong investment opportunity. The stock closed at $23.45 at the close of market yesterday.